Nina has often stated that Dimerix is fully funded for the phase 3 trials and that more deals are in the pipeline prior to phase 3 completion.
There is confidence in the science in the existing agreements. And researching the science and scientists involved - it further enhances that confidence.
DMX-200 (repagermanium), reduces the amount of proteinuria (when protein from your blood collects in your urine) and slows the decline of kidney function, when taken in addition to a medicine called an angiotensin II receptor blocker (ARB). An ARB is a very commonly used medicine in FSGS.
More agreement(s) could drop at any stage.
https://investors.dimerix.com/FormBuilder/_Resource/_module/WRxy8W0jV0SarmkfnUde8g/docs/DXB_A_Rare_Opportunit_2024.pdf
The above is a recent analysis performed by EUROZ HARTLEYS. It clarifies several points including:
1) The safety and efficacy of DMX 200 i.e.Last month the trial was de-risked when DXB announced DMX-200 had passed the efficacy futility analysis, indicating it is performing better than placebo. Importantly, this analysis represents a patient cohort nearly 10x larger than that of the phase 2 trial.
2) We estimate there is a +A$5 billion total addressable market (TAM) for DMX-200 in the treatment of FSGS.
3) Licensing Deal ⁄ Commercial Validation - DXB executed a major $230m licensing deal last year with European speciality pharma company Advanz Pharma, covering the European Economic Area, and other select regions. The deal could yield up to $220m in milestone payments for DXB, plus royalties of 15-20% on net sales. Additionally, DXB has received multiple non-binding term sheets for global and regional licensing deals, with a USA deal poised to be a major catalyst.
4) Fully Funded - The company is fully funded through to the completion of its phase 3 trial in FSGS with circa $38.6m in pro-forma cash, and an additional $7.7m of options in the money. Moreover, this cash could be supplemented by future licensing deals.
I am accumulating DXB shares - just like I accumulated NEU shares from $1.71 to $18.90 just last week (average $4)....
When you research DXB - it ticks all the boxes. DYOR. Start with Google! GLTAH.
- Forums
- ASX - By Stock
- DXB Media thread.
Nina has often stated that Dimerix is fully funded for the phase...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
|
|||||
Last
45.5¢ |
Change
-0.015(3.19%) |
Mkt cap ! $250.3M |
Open | High | Low | Value | Volume |
46.5¢ | 49.0¢ | 45.5¢ | $1.515M | 3.232M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 161532 | 45.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
46.5¢ | 33998 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 161532 | 0.455 |
5 | 65614 | 0.450 |
3 | 20200 | 0.445 |
5 | 123798 | 0.440 |
1 | 100000 | 0.435 |
Price($) | Vol. | No. |
---|---|---|
0.465 | 10000 | 1 |
0.470 | 21001 | 1 |
0.475 | 6000 | 1 |
0.480 | 2085 | 1 |
0.485 | 61748 | 3 |
Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |